PerkinElmer

cfDNA and cfRNA Analysis

Many challenges need to be overcome for reliable analysis of circulating DNA (cfDNA). To meet this need, PerkinElmer has developed complete, automated, end-to-end solutions ranging from blood fractionation, to DNA extraction, and cfDNA processing which simplify the process and improve the efficiency of the cfDNA analysis workflow.

For research use only. Not for use in diagnostic procedures.

Vanadis® System: Automated and Cost-Effective cfDNA Testing Platform

Unlike complex, expensive sequencing-based platforms, the Vanadis system enables cost-efficient cell-free DNA testing using standard microplates and automated sample processing – from primary blood tube to final data analysis. It’s so easy to use that one lab technician can handle up to 20,000 samples per year.

What makes the Vanadis system unique?

  • Innovative cfDNA testing platform which can be run by any laboratory
  • Fully automated workflow from sample to results
  • Scalable throughput to support evolving needs
  • Easy-to-use system with full traceability of samples and reagents
  • Integrated system software for remote workflow monitoring

Learn More

cfDNA and cfRNA Workflows

Changes in the levels of circulating nucleic acids are associated with certain disease conditions and could be useful for clinical applications, particularly for cancer patients and pregnant women. Significant research effort is being focused on developing clinical research reagents for prenatal disorders and malignant disease monitoring using DNA recovered from cell-free fluids.

Improving the Efficiency of cfDNA and cfRNA Workflows

Cell free DNA (cfDNA) is a sample type of choice due to its quick, very minimally-invasive method of collection that is amenable to analyzing multiple time points and multiple samples at a time when compared to more time-intensive, invasive methods such as tumor biopsy/fine-needle aspiration in cancer or chorionic villus sampling (CVS), or amniocentesis in prenatal testing research. Additional benefits for the use of cfDNA for oncology and other disorders include the provision of a big picture, real time snapshot of a comprehensive disease state and an intra-tumor heterogeneity profile at the time of detection and at relapse or metastasis, as opposed to what a local biopsy may offer.

Learn More

Interested in Learning More?